News and Media

January 18, 2023

2022 Update

2022 was a busy and productive year at Sustained Nano Systems. We entered the year with
the new SNS Densomere technology having already shown effectiveness in its ability to
release drugs over the long term ( our studies went out one year) and continue to maintain
its biologic activity. This was further proven by testing molecules placed into SNS
Densomeres by our pharmaceutical clients.

Life Sciences Summit Conference

January 9, 2022

SNS has been selected to present its Densomere Terminal Sterilization Technology at the ARVO (The Association for Research in Vision and Ophthalmology) meeting in Denver, May 1, 2022.

The ARVO Annual Meeting is the premiere gathering for eye and vision scientists at all career stages, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. The 2022 Meeting features both in-person and worldwide virtual participation options. Attendees will have opportunities to network with colleagues and industry thought-leaders.

Read the Abstract

August 17th, 2021

Selected to present at the HC Wainright Ophtomalogy conference

January 9th, 2020

Sustained Nano Systems, LLC to report on the extended release of medical cannabis at the Biotech Showcase in San Francisco, January 9, 2019.

Sustained Nano Systems selected to present at the biotech showcase in San Francisco.

October 2018

Sustained Nano Systems, LLC appoints Michael P. Goodman as Chief Financial Officer and Jan S. Peterson as Senior Regulatory Affairs Director.

Sustained Nano Systems to present at the American Academy of Ophthalmology annual convention.

Sustained Nano Systems achieves positive in-vitro results on long term sustained delivery of Latanaprost for glaucoma treatment.

Sustained Nano Systems appoints Morton Coleman, M.D. Director of Medical Oncology Board.

Sustained Nano Systems to present at the Life Science Summit in New York, November 1-2, 2017